



**HAL**  
open science

## Time trends in the incidence of conjunctival melanoma in Sweden

Eugenio Triay, Louise Bergman, Bo Nilsson, Charlotta All-Ericsson, Stefan  
Seregard

► **To cite this version:**

Eugenio Triay, Louise Bergman, Bo Nilsson, Charlotta All-Ericsson, Stefan Seregard. Time trends in the incidence of conjunctival melanoma in Sweden. *British Journal of Ophthalmology*, 2009, 93 (11), pp.1524-n/a. 10.1136/bjo.2009.157933 . hal-00477850

**HAL Id: hal-00477850**

**<https://hal.science/hal-00477850>**

Submitted on 30 Apr 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Time trends in the incidence of conjunctival melanoma in Sweden

Eugenio Triay <sup>1</sup>, Louise Bergman <sup>1</sup>, Bo Nilsson <sup>2</sup>, Charlotta All-Ericsson <sup>1</sup>, Stefan Seregard <sup>1</sup>

St. Eriks Eye Hospital, Karolinska Institutet<sup>1</sup> and Radiumhemmet, Karolinska Hospital, Karolinska Institutet<sup>2</sup>, Stockholm, Sweden.

Supported by grants from Karin Sandqvist's Foundation for the Visually Impaired, St. Eriks Eye Research Foundation and from the Swedish Research Council.

## Licence for Publication

The corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BJO and any other BMJ PGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<http://bjo.bmj.com/ifora/licence.pdf>).

Competing Interest: None declared

Corresponding author: Eugenio Triay, MD, St. Eriks Eye Hospital, Polhemsgatan 50, SE 112 82 Stockholm, Sweden; [eugenio.triay@sankterik.se](mailto:eugenio.triay@sankterik.se)

**PURPOSE.** To study time trends in the incidence of conjunctival melanoma in Sweden.

**METHODS.** All patients with conjunctival melanoma 1960 to 2005 in Sweden were identified through the Swedish Cancer Registry, cross-checked against hospital files and validated by histopathologic review (97.5%) or detailed hospital records (2.5%). The crude and age-standardized incidences were estimated separately for each gender and the annual change in incidence over time was estimated using a regression model with logarithmic incidence numbers. Time trends of the largest diameter, thickness and location of the tumor when diagnosed were analyzed.

**RESULTS.** The age-standardized incidence of conjunctival melanoma increased significantly in males (n = 89) from 0.10 cases/million to 0.74 cases/million (P = 0.001) and in females (n = 81) from 0.06 cases/million to 0.45 cases/million (P = 0.007). The annual relative change in age-standardized incidence was 16.9 % (95 % CI, 12.2 % - 21.6 %) in males and 19.5 % (95% CI, 9.3 % - 29.7 %) in females. The age-specific incidence was higher in men and women 65 years and older (1.48 and 1.39 cases/million, respectively) than in younger men and women (0.3 and 0.2 cases/million, respectively). During the period of study, tumors became smaller (P = 0.005) and thinner (P = 0.002) at the time of diagnosis and increasingly arose from parts of the conjunctiva exposed to ultraviolet radiation (P = 0.001).

**CONCLUSIONS.** The incidence of conjunctival melanoma increased in Sweden during the period 1960 through 2005.

Conjunctival melanoma arises from melanocytes lodged in the basilar layer of the conjunctival epithelium and causes death in 30 % or more of the patients.<sup>1</sup> Conjunctival melanoma is distinctly uncommon and though 95 % of all melanoma cases are cutaneous and 3-4 % of tumors occur in the eye, only about 5 % of melanoma arising in the ocular region has a conjunctival origin.<sup>2</sup> Population based studies indicate that the incidence of conjunctival melanoma is probably within the range 0.024 – 0.08 per 100,000.<sup>1,2,5-8</sup>

Given recent advances in the epidemiology and molecular biology of conjunctival melanoma, it now seems likely that the molecular mechanisms driving conjunctival melanoma tumorigenesis are more akin to those of cutaneous and mucous membrane melanoma than those of melanoma arising in the uveal tract.<sup>1,3-6</sup> Specifically, the incidence of cutaneous melanoma is increasing with 4 -5 % annually in the Western world and this rise is largely being attributed to increased exposure to ultraviolet radiation (UVR).<sup>8,9</sup> The uvea is largely protected from UVR exposure and uveal melanoma incidence rates appear stable or even declining.<sup>10</sup> Interestingly, large parts of the conjunctiva are exposed to UVR and recent studies suggest that conjunctival melanoma incidence rates may be rising and parallel those of cutaneous melanoma.<sup>5,6</sup>

## **MATERIALS AND METHODS**

The criteria for inclusion were patients with primary conjunctival melanoma, diagnosed in Sweden 1960 through 2005 with the diagnosis validated by histopathologic review by a trained ophthalmic pathologist or by detailed hospital records including clinical photographs or drawings. The Swedish National Cancer Registry, founded in 1958, receives reports when

a malignant disease is diagnosed. Compulsory dual registration from a clinician and a histopathologist or cytopathologist ensures a high inclusion rate. Each patient is identified through a unique national registration number, and the registry is estimated to include more than 95% of all cases of cancer in the country.<sup>11</sup> These data were combined with those of the Swedish Ocular Oncology Service and Eye Pathology Laboratory based at Karolinska University Hospital until 1990, and thereafter at St Eriks Eye Hospital in Stockholm. This tertiary referral centre manages nearly all cases of conjunctival and uveal melanoma in Sweden.

The research protocol for the present study was approved by the Human Ethics Committee at the Karolinska Institute, in accordance with the statutes of the World Medical Association's Declaration of Helsinki. Files from the Swedish National Cancer Registry during the period 1960 through 2005<sup>12</sup> were searched for patients with conjunctival melanoma, using both the International Classifications of Diseases, and the Seventh, Eight, Ninth and Tenth Revision (ICD-7, ICD-8, ICD-9 and ICD-10) code and the Systematized Nomenclature of Medicine (SNOMED) code. All the patients reported from Cancer Registry were cross-checked against the files of the Ocular Oncology Service and Eye Pathology Laboratory based in Stockholm. Data on the Swedish population were collected from the Statistics Sweden.<sup>13</sup>

During the study period, 170 cases of conjunctival melanoma were registered with the Swedish National Cancer Registry. A histopathologic review of archival tissue indicated that 21 cases were erroneously classified as conjunctival melanoma, as follows: 10 cases were choroidal melanoma, 5 iris melanoma, 3 ciliary body melanoma, 2 cutaneous melanoma and 1 case was a breast cancer. In addition, 14 patients were classified as conjunctival melanoma with the Swedish National Cancer Registry but as there no hospital records or histopathologic

samples to validate this, all 35 cases were excluded from this study, leaving 135 patients with conjunctival melanoma filed with the Swedish National Cancer Registry 1960 - 2005.

When searching our local pathology and hospital files, a total of 151 patients with conjunctival melanoma were found; 116 of these matched the files of the Swedish National Cancer Registry but 35 cases not previously registered were disclosed and formally notified. Hence, the Swedish National Cancer Registry's non-inclusion rate of conjunctival melanoma was 20.6 %. The 35 cases not previously registered were added to the 135 validated cases from the Swedish Cancer Registry leaving 170 patients with conjunctival melanoma to be included in this study; 166 (97.5 %) of these were confirmed by histopathologic examination and 4 (2.5 %) by detailed hospital records only. The size of each tumor was assessed from clinical photographs by two independent observers. The pathological grading and histological grade were assessed (tables 1-2). Most tumors were bulbar and multifocal (table 3).

Table 1

Pathological staging of primary tumour according to American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition (2009). Springer Science and Business Media ([www.springerlink.com](http://www.springerlink.com)). Reproduced with permission.

<i>Primary Tumor (pT)</i>	<i>Number of Cases</i>
pTX	14
pT1a	29
pT1b	48
pT1c	37
pT2a	4
pT2b	10
pT2c	19
pT3	9
Total	170

*Primary Tumor (pT)*

pTX	Primary tumor cannot be assessed
pT0	No evidence of primary tumor
pT(is)	Melanoma of the conjunctiva confined to the epithelium
pT1a	Melanoma of the bulbar conjunctiva not more than 0.5 mm in thickness with invasion of the substantia propria
pT1b	Melanoma of the bulbar conjunctiva more than 0.5 mm but not more than 1.5 mm in thickness with invasion of the substantia propria
pT1c	Melanoma of the bulbar conjunctiva greater than 1.5 mm in thickness with invasion of the substantia propria
pT2a	Melanoma of the palpebral, forniceal or caruncular conjunctiva not more than 0.5 mm in thickness with invasion of the substantia propria
pT2b	Melanoma more than 0.5 but not greater than 1.5 mm in thickness with invasion of the substantia propria.
pT2c	Melanoma of the palpebral, forniceal or caruncular conjunctiva greater than 1.5 mm in thickness with invasion of the substantia propria.
pT3	Melanoma invades the eye, eyelid, nasolacrimal system, sinuses or orbit
pT4	Melanoma invades the central nervous system

\*Note: pT(is) Melanoma in situ (includes the term primary acquired melanosis with atypia) replacing greater than 75 % of the normal epithelial thickness, with cytologic features of epithelioid cells, including abundant cytoplasm, vesicular nuclei or prominent nucleoli, and/or presence of intraepithelial nests of atypical cells.

Table 2

Histological grade of primary tumour according to American Joint Committee on Cancer (AJCC) Staging Manual, Seventh Edition (2009). Springer Science and Business Media ([www.springerlink.com](http://www.springerlink.com)). Reproduced with permission.

<i>Histological Grade (G)</i>	<i>Number of Cases</i>
GX	18
G0	0
G1	34
G2	0
G3	94
G4	24
Total	170

The histologic grade represents the origin of the primary tumor. Because this study only included invasive melanoma of the conjunctiva there is no case of G0 or G2.

GX	Origin cannot be assessed
G0	Primary acquired melanosis without cellular atypia
G1	Conjunctival nevus
G2	Primary acquired melanosis with cellular atypia (epithelial disease only)
G3	Primary acquired melanosis with epithelial cellular atypia and invasive melanoma
G4	<i>De novo</i> malignant melanoma

Table 3

Location of conjunctival melanoma

Location	Number of Cases
Bulbar, unifocal	39
Bulbar, multifocal	95
Bulbar + forniceal	1
Bulbar + tarsal	6
Bulbar + forniceal + tarsal	1
Tarsal	13
Forniceal	5
Caruncular	2
Caruncular + bulbar	5
Unknown	3
<b>Total</b>	<b>170</b>

Each gender was analyzed separately, and the patients were divided into eight age groups, each spanning 10 years, except the youngest (0 - 24 years) and the oldest (> 85 years) age groups. The analysis over time was performed for 5-year periods from 1960 except the period 2000 to 2005.

An overall crude and age-standardized incidence rate in the total Swedish population was calculated, and the genders were further analyzed separately. Age-standardization on incidence numbers over the study period was performed by a direct method, with the Swedish population during the period 1970 to 1974 taken as a standard, according to the stratum weights shown in table 4. The relative change in incidence over the 46-year period was calculated by linear regression after logarithmic transformation of incidence data. The annual change was expressed as a percentage with 95 % confidence intervals (CI). A similar regression model was used to estimate time trends in the largest diameter, thickness and location of the tumor when at diagnosed. Tumor location was coded as conjunctiva chronically exposed to ambient solar radiation and hence UVR (most of the bulbar and limbal



and all caruncular conjunctiva) or as conjunctiva with minimal UVR exposure (tarsal and forniceal conjunctiva). The level for statistical significance was a set at  $P < 0.01$ . Data were processed with statistical-analysis software (SPSS, ver. 15.0; SPSS Inc., Chicago, IL).

Age groups (y)	Males	Females
0-24	0.36	0.34
25-34	0.15	0.14
35-44	0.11	0.11
45-54	0.13	0.13
55-64	0.12	0.12
65-74	0.08	0.10
75-84	0.04	0.05
>85	0.01	0.01

Table 4

Stratum Weights of the Swedish Population during the period 1970 to 1974

## RESULTS

A total of 170 patients were found to have conjunctival melanoma in Sweden during the period 1960 through 2005 after searching the Swedish National Cancer Registry and the files of the Swedish Ocular Oncology Service and Eye Pathology Laboratory. These patients included 89 men and 81 women (male to female ratio: 1, 09). The men were 20 to 99 years of age (mean = 62 years; median = 63 years), and the women ranged from 22 to 91 years of age (mean = 67 years; median = 75 years) at the time of diagnosis. Notably, all patients were 35 years of age or older at the time of diagnosis with the exception of 2 patients (Fig 1).

### Age distribution of incidence




Figure 1

The age distribution of conjunctival melanoma in the Swedish population during the period 1960 through 2005.

The age-specific incidence for men and women increased gradually from the 35 - 44 years of age group (0.49 and 0.19 cases per million, respectively) to peak for the group > 85 years of age at the time of diagnosis (3.27 and 2.95 cases per million, respectively). The age-specific incidence was higher in men and women 65 years and older (1.48 and 1.39 cases/million, respectively) than in men and women younger than 65 years of age (0.3 and 0.2 cases/million, respectively) at the time of diagnosis (Fig 2).





Figure 2


Age-specific incidence rates of conjunctival melanoma in the population of Sweden during the period 1960 through 2005.

During the period 1960 through 2005, the overall age-standardized incidence of conjunctival melanoma in the Swedish population increased 7-fold, from 0.08 cases/million to 0.56 cases/million ( $P = 0.001$ ). In the male population, the age-standardized incidence increased from 0.10 to 0.74 cases/million ( $P < 0.001$ ) and this was paralleled by a similar increase among women from 0.06 to 0.45 cases/million ( $P = 0.007$ ) during the period of study (Fig 3). By applying a log regression model, we determined the annual change in incidence rate. The male incidence increased by 16.9 % (95 % CI, 12.2 % – 21.6 %) yearly and the female incidence increased by 19.5 % (95 % CI, 9.3 % - 29.7 %) annually from 1960 to 2005. The total annual change in incidence for both genders combined was 17.1 % (95 % CI, 11.2 % - 23.0 %).

A



B



C




Figure 3

Annual age-standardized incidence compared to the observed incidence in the Swedish population for (A) males, (B) females and (C) both genders combined during the period 1960 through 2005. *Solid line*: observed incidence; *broken line*: age-standardized rates when standardized against the Swedish population of 1970 to 1974.

By logarithmic regression, the largest tumor diameter at the time of diagnosis decreased from 11 to 8 mm (P for slope = 0.005) and tumor thickness decreased from 2.5 to 1.0 mm (P for slope = 0.002) during the period of study. Most of the increase in conjunctival melanoma incidence could be attributed to melanoma becoming more frequent in bulbar parts of the conjunctiva exposed to ultraviolet radiation (Fig 4).




Figure 4

Model-based fitted values with linear regression shown no significant increase in conjunctival melanoma arising from conjunctiva protected from ultraviolet radiation (P for slope 0.275), but tumors arising from conjunctiva exposed to ultraviolet radiation increased (P for slope < 0.001) during the period of study. The difference between slopes was statistically significant (P = 0.001). The total number of cases of UV-exposed conjunctival melanoma was 134. The number of UV-nonexposed conjunctival melanoma was 33. In three cases it was not possible to completely identify the location of the tumor.

## DISCUSSION

This study demonstrates a dramatic and statistically significant increase in the incidence of conjunctival melanoma in Sweden 1960 through 2005. Are these results correct? There have been two recent studies on time trends in conjunctival melanoma incidence based on closely similar but not identical datasets from the National Cancer Institute's Surveillance Epidemiology, and End Results (SEER) program. The SEER database covered in 1992 approximately 14 % of the population of the United States.<sup>9</sup>

One of the previous studies based on the SEER database detected 153 cases of conjunctival melanoma during the period 1974 – 1998;<sup>9</sup> the other found 206 cases when including only 2 more years, from 1973 to 1999.<sup>5</sup> Whilst the first study failed to detect a statistically significant increase in conjunctival melanoma incidence,<sup>9</sup> the second study detected a biennial increase of 11.2 % (95 % CI; 6.3 – 16.3) in White men.<sup>5</sup> Remarkably this rise was not seen in women. In contrast, the study reported herein is the first to demonstrate a statistically significant increase in the incidence of conjunctival melanoma for both males and females with no apparent gender difference. Similarly, a previous study found no difference between genders suggesting that in Finland, the rise in conjunctival melanoma incidence largely parallels the increase seen in cutaneous melanoma incidence.<sup>6</sup>

A rise in cutaneous melanoma incidence is apparent in many Western countries and in Sweden a 5 % annual increase has been reported during 1976 through 1994.<sup>14</sup> Notably, the 17.1 % (95 % CI; 11.2 % - 23.0 %) annual increase of the incidence we report is more than 3 times the rise in cutaneous melanoma incidence in a near identical population.<sup>14</sup> There are

many potential flaws to consider before accepting this sharp rise in incidence. Firstly, the completeness of registration may have been incomplete during the early years of the study, giving rise to ascertainment bias. However, the proportion of cases validated by histopathologic examination remained high throughout the period of study reported herein. Also, data derived from both types of sources (National Registry and Ocular Oncology Centre) included in this study showed a similar trend with incidence rising from 1970 and reaching a plateau after 1990. Interestingly, this plateau parallels the levelling off noticed for cutaneous melanoma incidence in Northern Europe since the mid 1990s.<sup>15</sup>

Secondly, the incidence of conjunctival melanoma in Sweden during the first period of the study (from 1960 to the mid 1970s) was lower (0.08 to 0.20 per million) than the crude annual incidence reported from neighbouring countries like Finland with a mean of 0.4 per million<sup>6</sup>, or Denmark with 0.45 cases per million.<sup>8</sup> The low incidence seen in Sweden until the mid 1970s would somewhat accentuate the rise in incidence seen in later years.

Thirdly, because the incidence of conjunctival melanoma differs markedly between ethnically different populations,<sup>16</sup> a rising incidence occurring through a long period of time could be (partially) explained by an ethnicity shift of that population. The SEER population includes 14 % of the United States population and is more much more ethnically heterogenous (including higher proportions of Blacks and Hispanics with a lower incidence rate) than the Swedish population, which like the Finnish population is largely made up of Whites.<sup>16</sup> Notably, there has been a small but growing immigration from both European and non-European countries to Sweden in the past few decades.<sup>14</sup> However, the net immigration rate remains comparatively low: the Swedish rate is estimated at 0.86/1000 population compared with 3.5/1000 population for the United States during 2000.<sup>17</sup> Data from the Swedish

National Bureau of Statistics indicate that the proportion of the population of non-European origin in 1960 was 0.2 % and in 1998 had increased to 4.0 %.<sup>18</sup>

Fourthly, diverse factors might explain the increase of reported cases to the Swedish National Cancer Registry during the recent decades as, for instance, health awareness of the population or a higher accessibility to ophthalmologic examination through the expansion of cataract surgery and screening programs for diabetic retinopathy that has been introduced in the last twenty five years. However, only very small subsets of the Swedish population have annual ophthalmological follow-up. The statistically significant decrease of the largest tumor diameter and tumor thickness we noted is consistent with lesions being diagnosed at an earlier stage in recent years, but even so this is insufficient to fully account for the increase in overall incidence observed throughout the 46-years period of the study.

Increased intermittent UVR exposure through ambient sunlight has been directly implicated in the significant rise in cutaneous melanoma incidence apparent in fair skinned societies.<sup>15</sup> Not much evidence is available on the pathogenesis of conjunctival melanoma, but as most of the conjunctiva is UVR exposed, it is conceivable that any rise in conjunctival melanoma incidence could be attributed to similar molecular mechanisms as in the pathogenesis of cutaneous melanoma.<sup>2</sup> Interestingly, the rise in conjunctival melanoma incidence we have shown in this study could largely be attributed to conjunctival melanoma occurring more frequently in conjunctiva exposed to UVR. Similarly, there was no detectable increase in conjunctival melanoma arising from the tarsal conjunctiva (outlining the inner surface of the eyelids) with minimal sunlight exposure. Taken together with the time trend, this suggests that UVR exposure may play a major part in the pathogenesis of conjunctival melanoma.



## REFERENCES

- 1 **Seregard S**, Conjunctival Melanoma. *Surv Ophthalmol* 1998;42:321-350.
- 2 **Seregard S**, Triay E. New aspects on the pathogenesis of the conjunctival melanoma, Krieglstein GK, Weinreb RN. *Cornea and external eye disease*. Berlin, Springer, 2008; 197-212.
- 3 **Li L**, Hu DN, Zhao H, et al. Uveal melanocytes do not respond to or express receptors for alpha-melanocyte stimulating hormone. *Invest Ophthalmol Vis Sci* 2006;47:4507-4512.
- 4 **Henkind P**, Friedman AH. External ocular pigmentation. *Int Ophthalmol Clin* 1971;11:87-111.
- 5 **Yu GP**, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? *Am J Ophthalmol* 2003;135:800-806.
- 6 **Tuomaala S**, Eskelin S, Tarkkanen A, Kivela T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. *Invest Ophthalmol Vis Sci* 2002;43:3399-3408.
- 7 **Missotten GS**, Keijser S, De Keizer R, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: A nationwide study. *Invest Ophthalmol Vis Sci* 2005;46:75-82.
- 8 **Isager P**, Österlind A, Engholm G, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943-97: Incidence and validation study. *Ophthalmic Epidemiol* 2005; 12:223-232.
- 9 **Inskip PD**, Devesa SS, Fraumeni JF. Trends in the incidence of ocular melanoma in the United States, 1974-1998. *Cancer causes and control* 2003;14:251-257.
- 10 **Bergman L**, Seregard S, Nilsson B, et al. Incidence of uveal melanoma in Sweden from 1960 to 1998. *Invest Ophthalmol Vis Sci* 2002;43:2579-2583.

- 11 **Mattson B**, Wallgren A. Completeness of the Swedish Cancer Register: non-notified cancer cases recorded on death certificates in 1978. *Acta Radiol (Oncol)* 1984;23:305-313.
- 12 **The Cancer Registry**: Cancer incidence in Sweden. Stockholm: National Board of Health and Welfare. *Annual publications*. 1960-2005.
- 13 **Official Statistics of Sweden**. Stockholm: Statistics Sweden; *Annual publications* 1960-2005.
- 14 **Månsson-Brahme E**, Johansson H, Larsson O, et al. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. *Acta Oncol* 2002;41:138-146.
- 15 **de Vries E**, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decrease in Scandinavia. *Int. J. Cancer* 2003; 107:119-126.
- 16 **Hu DN**, Yu G, McCormick, Finger PT. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanoma. *Am J Ophthalmol* 2008;145:418-423.
- 17 **Publications and reports**. *The World Fact Book 2000*. Washington, DC: Central Intelligence Agency; 2000. Available at <http://www.odci.gov/cia/publications/factbook/indexgeo.html>. Accessed February 4, 2008.
- 18 **Official Statistics of Sweden**. Stockholm: Statistics Sweden; *Annual Publications* 1960-1998